Antiplatelet Effectivity between Aspirin with Honey on Cardiovascular Disease Based on Bleeding Time Taken on Mice.
Antiplatelet
Bleeding time
Honey
Journal
Open access Macedonian journal of medical sciences
ISSN: 1857-9655
Titre abrégé: Open Access Maced J Med Sci
Pays: North Macedonia
ID NLM: 101662294
Informations de publication
Date de publication:
30 Oct 2019
30 Oct 2019
Historique:
received:
14
08
2019
revised:
15
09
2019
accepted:
16
09
2019
entrez:
1
2
2020
pubmed:
1
2
2020
medline:
1
2
2020
Statut:
epublish
Résumé
The prevalence of cardiovascular disease (CVD) and its mortality continues to increase. Various studies have shown aspirin can reduce CVD mortality but has adverse side effects. Research on a comparison between aspirin and honey has not been done, but both have antiplatelet effects. This study is aimed to prove the antiplatelet effects on honey and compare the antiplatelet effects of aspirin with honey based on the bleeding time in mice. This study is a true experimental design with a post-test only control group using 32 male mice, Double Ditsch Webster, ± 3 months old, the weight of 20-30 g, divided into 4 groups. Consisting of a negative control group (placebo), aspirin and honey. The suspension has given orally for 12 days using the probe. The research was conducted at the Laboratory of Pharmacology Department of Pharmacology and Therapeutics Faculty of Medicine, the University of North Sumatra in September until December 2015. The data collected was bleeding time in mice. Data analysed by Shapiro Wilk test, Kruskal Wallis and Mann Whitney. The mean bleeding time was a placebo (102.88 seconds), aspirin (369.38 seconds) and honey (304.63 seconds). Mann Whitney test showed significant results in the aspirin and honey groups against the control group (placebo) with p = 0.001. There were no significant differences in the aspirin group against honey (p = 0.172). Honey has an antiplatelet effect in mice. The mean bleeding time in mice given honey is longer or closer to the mean bleeding time in the aspirin group. The results could be used as a basis for further research to determine its use in humans with cardiovascular disease.
Sections du résumé
BACKGROUND
BACKGROUND
The prevalence of cardiovascular disease (CVD) and its mortality continues to increase. Various studies have shown aspirin can reduce CVD mortality but has adverse side effects. Research on a comparison between aspirin and honey has not been done, but both have antiplatelet effects.
AIM
OBJECTIVE
This study is aimed to prove the antiplatelet effects on honey and compare the antiplatelet effects of aspirin with honey based on the bleeding time in mice.
METHODS
METHODS
This study is a true experimental design with a post-test only control group using 32 male mice, Double Ditsch Webster, ± 3 months old, the weight of 20-30 g, divided into 4 groups. Consisting of a negative control group (placebo), aspirin and honey. The suspension has given orally for 12 days using the probe. The research was conducted at the Laboratory of Pharmacology Department of Pharmacology and Therapeutics Faculty of Medicine, the University of North Sumatra in September until December 2015. The data collected was bleeding time in mice. Data analysed by Shapiro Wilk test, Kruskal Wallis and Mann Whitney.
RESULTS
RESULTS
The mean bleeding time was a placebo (102.88 seconds), aspirin (369.38 seconds) and honey (304.63 seconds). Mann Whitney test showed significant results in the aspirin and honey groups against the control group (placebo) with p = 0.001. There were no significant differences in the aspirin group against honey (p = 0.172). Honey has an antiplatelet effect in mice. The mean bleeding time in mice given honey is longer or closer to the mean bleeding time in the aspirin group.
CONCLUSION
CONCLUSIONS
The results could be used as a basis for further research to determine its use in humans with cardiovascular disease.
Identifiants
pubmed: 32002064
doi: 10.3889/oamjms.2019.431
pii: OAMJMS-7-3416
pmc: PMC6980826
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3416-3420Informations de copyright
Copyright: © 2019 Sake Juli Martina, Logaselvi A.P. Ramar, Michael R.I. Silaban, Muhammad Luthfi, Pradeepa A.P. Govindan.
Références
Evid Based Complement Alternat Med. 2009 Mar;6(1):113-21
pubmed: 18955249
Chin J Physiol. 2007 Jun 30;50(3):121-6
pubmed: 17867432
J Mol Cell Cardiol. 2009 Mar;46(3):309-17
pubmed: 19133271
Atherosclerosis. 2007 Sep;194(1):144-52
pubmed: 17092506
Antioxid Redox Signal. 2004 Aug;6(4):747-56
pubmed: 15242556
BMJ. 2002 Jan 12;324(7329):71-86
pubmed: 11786451
Pak J Pharm Sci. 2011 Jul;24(3):389-97
pubmed: 21715274
Am J Emerg Med. 2001 Sep;19(5):337-95
pubmed: 11555795
Chest. 2004 Sep;126(3 Suppl):234S-264S
pubmed: 15383474